What Does Elevated Troponin Mean in COVID-19?

Allan Jaffe

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Ken Fujioka

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Defining the Epidemiologic Scope of Cardio-Kidney-Metabolic Syndrome

The Texas Heart Institute

A. Pandey

Cardio-Renal Syndrome Management: What Are the Key Factors That Impa…

Patricia Kao

Cancer Before Solid Organ Transplant

Fred Hutchinson Cancer Center

C. Blosser

New Approaches to the Treatment of IgA Nephropathy

Leicester IgA Nephropathy

J. Barratt

APOL1 Controversies Conference Plenary: APOL1 Pathophysiology

KDIGO

D. Friedman

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

Social Determinants of Health for Cardiovascular Kidney Metabolic Sy…

Kibret Enyew Belay

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

KDIGO Scientific Symposium on the Impact of Viral Infection and the …

KDIGO

S. Chadban, U. Huynh-Do, M. Jadoul, D. Kumar

EADV 2024 Insights: Calciphylaxis

EADV 2024 Insights

C. Erfurt-Berge

Interview with IgA Nephropathy Patient Alistair

Leicester IgA Nephropathy

L. Iga Nephropathy

Treatment of Fabry Disease

Ankit Mehta